ClinicalTrials.gg
CompletedNCT02755857Updated Oct 26, 2018

Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis

A Phase 2 interventional study of Lozanoc in Neutropenia, sponsored by Mayne Pharma International Pty Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-26.

Sponsored by Mayne Pharma International Pty Ltd · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Neutropenia with a site in Australia — 1 open to participants now, 1 under way, 1 of them phase 3. Neutropenia · Australia.

Started
2016
the only one that year
Phase 2
3 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
2 of 10
Mayne Pharma International Pty Ltd

Among the 10 studies in Neutropenia with a site in Australia, this one is the only one that started in 2016, is one of 3 in phase 2, and was the 9th registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

1 of the 10 studies in Neutropenia with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Neutropenia with a site in Australia, or all of them as a file.
02

Study summary

This open-labelled, single arm study is a follow-on from Study MPG010 to compare the relative bioavailability of Lozanoc 65 mg Capsules against Lozanoc 50 mg Capsules and Sporanox 100 mg Capsules in patients requiring itraconazole anti-fungal prophylaxis.

Read the detailed description

After confirmation of eligibility, participants will take their last dose of current itraconazole therapy (Lozanoc 50mg capsules or Sporanox 100mg capsules) on the morning of Day 1, and commence therapy with Lozanoc 65 mg capsules for 21 days from the evening of Day 1.

The number of Lozanoc 65mg capsules to be taken by the participant will be 2 capsules (130mg) morning and evening OR the same number of Lozanoc 50mg capsules that the participant received in study MPG010, if applicable. That is, if the participant received 3 x 50mg Lozanoc capsules morning and evening on study MPG010 he/she will receive 3 x 65 mg Lozanoc 65 mg capsules, morning and evening in study MPG011

The dose of study drug (Lozanoc 65mg) may be dose-reduced or ceased for toxicity at the discretion of the investigator.

Participants will undergo the following assessments during the course of the study:

  • Concurrent medication(s)
  • Clinical adverse events
  • Measurement of vital signs (weight, blood pressure, temperature)
  • Targeted physical examination
  • Documentation of any evidence of systemic fungal infection
  • Medication and meal diaries
  • 12-lead electrocardiogram (ECG)
  • Laboratory safety assessments

    • Renal function and electrolytes (urea, creatinine, estimated glomerular filtration rate [eGFR], sodium, potassium, chlorine, bicarbonate)
    • Liver function tests (bilirubin, albumin, total protein, alanine aminotransferase [ALT], aspartate aminotransferase [AST])
  • Pharmacokinetic testing

    • pre-morning dose (0 h sample) at Baseline (Day 1), and at Days 8, 15, and 22
    • at 2, 3.5 and 6 hours post the morning dose at Baseline (Day 1) and Day 22
03

Conditions studied

  • Neutropenia

Browse trials for

Keywords

  • Prophylaxis
  • Bioavailability
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written,
  • Age of at least 18 years
  • No clinical evidence of active systemic fungal infection
  • Physician-recommended continuation of oral itraconazole as primary prophylaxis in patients at risk of systemic fungal infections or otherwise requiring a long-term itraconazole maintenance regimen, including patients:

    • who have had or are about to have a heart, lung or bone marrow transplant
    • on combination chemotherapy for cancer
    • with an aspergilloma, chronic pulmonary aspergillus bronchitis, or allergic bronchopulmonary aspergillosis
  • At least 21 days of prior dosing with oral itraconazole, either Lozanoc 50mg capsules twice daily or Sporanox 100mg capsules twice daily.
  • between 15.0 and 35.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Pregnant, planning pregnancy or breastfeeding
  • Plasma itraconazole concentration greater than 1500ng/mL (in patients on Lozanoc 50mg capsules)
  • Congestive cardiac failure or other causes of ventricular dysfunction that may outweigh the benefit of itraconazole
  • to Lozanoc or to any of its
  • Coadministration of the following drugs:

    • metabolised substrates that can prolong the -interval: sertindole, terfenadine
    • CYP3A4 metabolised 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors: simvastatin, lovastatin
    • Potent CYP3A4 inhibitor: dronedarone
    • Triazolam, alprazolam and oral midazolam
    • Ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine) and ergotamine
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Lozanoc

    65 mg, capsules, at least 2 capsules twice a day

    Drug: Lozanoc

Interventions

  • 65 mg

    Also known as: itraconazole

06

What researchers measure

Primary outcomes

  1. Steady-state plasma itraconazole concentrations

    Time frame: 3 weeks

07

Study locations

1 site
  • St Vincent's Hospital
    Darlinghurst, New South Wales 2010, Australia
08

References and documents

Individual participant data

Plan to share: No — Individual patient data will not be made available

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Dec 2016, 5 months.

Of 25 phase 2 interventional studies under Neutropenia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2016
First posted
Apr 29, 2016
StartActual
Jul 2016
Primary completionActual
Dec 2016
CompletionActual
Jan 2017
Last update
Oct 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02755857
Lead sponsor
Mayne Pharma International Pty Ltd
Responsible party
Sponsor
First posted
Apr 29, 2016
Start date
Jul 2016
Primary completion
Dec 2016
Completion
Jan 2017
Last update
Oct 26, 2018

Study contacts

Deborah Marriott, MBBS BSc(MED) FRACP FRCPA
principal investigator · St Vincent's Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itraconazole

Start the discussion